Publications by authors named "Elke M Erne"
Article Synopsis
- Tick-borne encephalitis virus (TBEV), spread through tick bites, mostly causes mild illness in over 90% of cases, but can lead to varying degrees of encephalitis in some individuals.
- Around 10% of patients with severe TBE in Austria, Czech Republic, and France have auto-antibodies (auto-Abs) that neutralize certain types of interferon (IFN), which are important for immune response, while only about 1% of patients with milder symptoms have them.
- The presence of these auto-Abs significantly increases the risk of severe TBE, with odds ratios indicating up to a 20.8 times higher chance of severe illness when these auto-Abs are
Article Synopsis
- Persistent infections from a specific nematode in elderly Italians are likely more common than realized, often remaining asymptomatic for years.
- The nematode can reactivate and cause a variety of symptoms, which can lead to misdiagnosis despite suggestive clinical signs.
- This report highlights two complex cases of strongyloidiasis that presented with skin lesions, aiming to educate clinicians on recognizing signs that imply an underlying infection.
Background: Comparative data on mortality in COVID-19 patients treated with molnupiravir or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause mortality in community-dwelling COVID-19 patients treated with these drugs during the Omicron era.
Methods: Data collected in the nationwide, population-based, cohort of patients registered in the database of the Italian Medicines Agency (AIFA) were used.
Article Synopsis
- A population pharmacokinetic analysis of dalbavancin assessed its effectiveness in patients with various infections using non-linear mixed effect modeling and Monte Carlo simulations.
- The study included 69 patients, mostly with bone and joint infections, and found that creatinine clearance was the key factor influencing dalbavancin clearance.
- Results indicated that dosage adjustments based on renal function are crucial, with specific recommendations for single or double doses of 1000 mg or 1500 mg to ensure optimal effectiveness over different time periods.
We report a case of a woman who experienced psychiatric disorders after switching her antiretroviral therapy (c-ART) to dolutegravir (DTG). She is a 59-year-old HIV-1 positive woman with a recent story of cardiovascular disorders treated with beta-blockers, clopidogrel, and rosuvastatin. She underwent a c-ART switch from darunavir/cobicistat and maraviroc to emtricitabine/tenofovir alafenamide fumarate in association with dolutegravir due to drug-drug interactions.
View Article and Find Full Text PDFBackground & Aims: Advances in direct-acting antiviral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact of only diagnosed and linked-to-care individuals on overall HCV burden estimates and identified a possible strategy to achieve the WHO targets by 2030.
Methods: Using a modelling approach grounded in Italian real-life data of diagnosed and treated patients, different linkage-to-care scenarios were built to evaluate potential strategies in achieving the HCV elimination goals.
Unlabelled: We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus-infected patients: policy 1, "universal," treat all patients, regardless of fibrosis stage; policy 2, treat only "prioritized" patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus-infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were used to evaluate the policies' cost-effectiveness.
View Article and Find Full Text PDFThe evolution of hepatitis B virus (HBV) and the role of different variants during antiviral therapy may be influenced by HBV genotype. We have therefore analysed substitutions potentially related to nucleos(t)ide analogues (NAs) resistance at 42 positions within RT-region in a cohort of patients with chronic hepatitis B in relation to HBV-genotype. RT mutations analysis was performed by direct sequencing in 200 NAs-naïve patients and in 64 LAM or LAM+ADV experienced patients with NAs resistance, infected mainly by HBV-genotypes D and A.
View Article and Find Full Text PDF